A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
about
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia APrimary percutaneous coronary intervention for acute myocardial infarction in a young female with idiopathic thrombocytopenic purpura: a case report and review.Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals.Platelets as delivery systems for disease treatmentsSuccessful Ultrasound-Guided Femoral Nerve Blockade and Catheterization in a Patient with Von Willebrand DiseaseUtility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.Development and introduction of recombinant factor VIII--a clinician's experience.A review of immune tolerance induction with Haemate P in haemophilia A.Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.Acquired hemophilia as the cause of life-threatening hemorrhage in a 94-year-old man: a case report.Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.
P2860
Q26738507-25F6D3D3-90C7-4A8B-901A-9FD07C517A35Q33756642-402C72A4-0DC8-4F89-B366-8C5391EFB6DCQ34183076-FB5639EC-E427-429C-A4B0-502AABCD0A9BQ34348837-07A26953-002A-4067-AEFE-D0921C3A0201Q35737576-665C555F-738D-4751-9193-80FA8AD4D32EQ35846930-46D410FE-7172-4EC4-9581-5954E43DD4BDQ37230340-C430A676-2E7B-4B72-9A55-73ED12321AC8Q37357218-379CBE65-EBAC-4594-BFB3-2269E9E1144FQ37645977-FEC3FB32-ECB9-4C5C-AFF8-6586F290219AQ37813807-23039531-D44D-4597-A7F1-79D3200DF31BQ38003396-259492F7-8E93-4185-8039-4818A3DAE728Q38156000-407670AD-DAF6-4A48-94D0-244CADF3D3A4Q38900471-432A1572-8A8E-488E-AA1D-EFDCEFA99897Q41871660-DA23D23F-2E15-44CA-9A7C-D76DC2F37D9AQ45864439-FCD040C6-D1AC-4B4A-8A2E-B2373BEF0FD6Q45871507-F441024E-700A-416D-A7EE-61A3EA3E87A8
P2860
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic overview of the f ...... tory and clinical performance.
@en
A systematic overview of the f ...... tory and clinical performance.
@nl
type
label
A systematic overview of the f ...... tory and clinical performance.
@en
A systematic overview of the f ...... tory and clinical performance.
@nl
prefLabel
A systematic overview of the f ...... tory and clinical performance.
@en
A systematic overview of the f ...... tory and clinical performance.
@nl
P2093
P2860
P1476
A systematic overview of the f ...... tory and clinical performance.
@en
P2093
Augusto B Federici
Erik Berntorp
Günter Auerswald
Hartmut Pollmann
Inge Scharrer
Keith Hoots
Sigurd Knaub
Stefan Lethagen
William Archey
Wolfhart Kreuz
P2860
P356
10.1111/J.1600-0609.2008.01049.X
P577
2008-05-01T00:00:00Z